Eight IPOs raised a combined $1.2 billion in October, joined by one direct listing. Activity was well below the month’s 10-year historical average (22 IPOs, $5.1B). Six IPOs raised $100 million or more. With AI stocks under pressure in recent weeks,...read more
Three IPOs, one direct listing, and two SPACs priced during a challenging week for growth stocks. However, the week’s most notable news came from Anthropic (ANT), which filed its long awaited S-1 on Monday for an IPO that could be the largest ever. ...read more
Aspen Neuroscience, a Phase 1/2a biotech developing stem cell therapies for Parkinson’s disease, raised $141 million by offering 9.4 million shares at $15, the low end of the $15 to $17 range. At pricing, the company commands a fully diluted market value...read more
Aspen Neuroscience, a Phase 1/2a biotech developing stem cell therapies for Parkinson’s disease, announced terms for its IPO on Monday. The San Diego, CA-based company plans to raise $150 million by offering 9.4 million shares at a price range of $15 to...read more
Renaissance Capital’s October IPO Market Update
Eight IPOs raised a combined $1.2 billion in October, joined by one direct listing. Activity was well below the month’s 10-year historical average (22 IPOs, $5.1B). Six IPOs raised $100 million or more. With AI stocks under pressure in recent weeks,...read more
US IPO Weekly Recap: Anthropic files for potentially record-breaking IPO
Three IPOs, one direct listing, and two SPACs priced during a challenging week for growth stocks. However, the week’s most notable news came from Anthropic (ANT), which filed its long awaited S-1 on Monday for an IPO that could be the largest ever. ...read more
Parkinson’s disease biotech Aspen Neuroscience prices IPO at $15, the low end of the range
Aspen Neuroscience, a Phase 1/2a biotech developing stem cell therapies for Parkinson’s disease, raised $141 million by offering 9.4 million shares at $15, the low end of the $15 to $17 range. At pricing, the company commands a fully diluted market value...read more
Parkinson’s disease biotech Aspen Neuroscience sets terms for $150 million IPO
Aspen Neuroscience, a Phase 1/2a biotech developing stem cell therapies for Parkinson’s disease, announced terms for its IPO on Monday. The San Diego, CA-based company plans to raise $150 million by offering 9.4 million shares at a price range of $15 to...read more